NASDAQ OMX

Dubuc Motors Receives SEC Qualification Under US JOBS Act

Del

MENLO PARK, Calif., 2017-02-23 14:00 CET (GLOBE NEWSWIRE) --

Dubuc Motors, the company behind the Tomahawk – the world’s first 2+2 electric sports car, announced today the launch of the live offering phase of its equity crowdfunding campaign after the qualification of its filing with the Securities and Exchange Commission (SEC). The company revealed its electric supercar through a Testing the Waters (TTW) campaign in 2016 and is now turning the $6 million in initial funding reservations into real funding dollars.

Photos accompanying this release are available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/309423be-9f0e-4bb4-a283-e15b58f02cef

http://www.globenewswire.com/NewsRoom/AttachmentNg/f25348fd-fd59-4b47-80e1-2091fcd0a8a2

http://www.globenewswire.com/NewsRoom/AttachmentNg/08e99abb-337a-4a13-b0b6-13947acbb376

http://www.globenewswire.com/NewsRoom/AttachmentNg/017a706a-045a-4e98-b6c9-b054ad12ff30

Under Title IV of the JOBS Act, Regulation A+, Dubuc Motors can begin to convert reservations into equity shares. The company regards itself as the first company to jointly conduct a Regulation S offering with a Regulation A, allowing for investors to contribute as little as $200 in the United States as well as internationally. The company will be a low volume manufacturer, with an expected production of up to 1500 units per year.

“People have embraced the idea that the Tomahawk, although an exotic sports car, can be as practical as a sedan,” said Mike Kakogiannakis, co-founder of Dubuc Motors. “We are seeing the incredible response from investors and it’s exciting to see a big community of game changers and trend setters jump on board as shareholders early on."

The 370-mile range Tomahawk caters to a unique audience, entering the market as the first and only electric all-wheel drive 2+2 sports car. The car accommodates the big and tall, seating drivers up to 6’5” comfortably. Additional features such as rear seats and trunk space add utility, making the Tomahawk an everyday luxury sports car. The Tomahawk is now available for purchase on the company’s website and customers can reserve early with a $5,000 deposit, securing their vehicle for 2018.

About Dubuc Motors: 
Dubuc Motors is the company behind the Tomahawk - the world’s first 2+2 electric sports car. Self-funded since the company's launch in 2013, Dubuc Motors spent 13 years in research and development to create a luxury sports car that merges automotive power with sustainability.

The Tomahawk features top quality performance, going 0-60 mph in 3 seconds while offering a 370-mile range. The company is focused on providing a luxury sports vehicle experience that is sleek yet spacious, and Mother Nature-approved. The vehicle is now available for reservation and will be unveiled in 2018.

For more information or to commit funding on the equity crowdfunding campaign, please visit www.dubucmotors.com

Regulation A Disclaimer:

An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that Dubuc may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from: 
https://www.sec.gov/Archives/edgar/data/1688361/000168836117000008/dubform1a-02212017.htm

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You should read the offering circular before making any investment.

         Contact: Daniella Ruiz
         BAM Communications
         C: 619.788.1556
         Daniella@bamcommunications.biz

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00Pressemelding

Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.  

World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25Pressemelding

YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p

Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30Pressemelding

CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC.                                                               Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S.  DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12Pressemelding

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On

Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations se

World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16Pressemelding

YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom